Last Name


Search Results to Alan S. Gamis

This is a "connection" page, showing the details of why an item matched the keywords from your search.


One or more keywords matched the following properties of Gamis, Alan

research overview Dr. Gamis' research expertise is in the design and development of multi-institutional clinical trials in childhood cancer, specifically in AML. He is a board certified Pediatric Hematologist/Oncologist and continues to care for patients with cancer in a large children's cancer center. He also trained as an Epidemiologist receiving an MPH in 1991 as a foundation for clinical trial development. He has been active in AML research activities in the Children's Oncology Group since 1993, first serving on several COG clinical trial committees (AML, Neuroblastoma, Hodgkin’s, Stem Cell Transplant, Epidemiology, & Supportive Care/Nursing), then chairing two large clinical trials. The first was the first phase III trial specifically for children with AML and Down Syndrome, COG A2971 - Treatment of Children with Down’s Syndrome and AML, MDS, and Transient Myeloproliferative Disorder, from 1996-2004.This was followed by a second national Phase III trial, COG-AAML0531- Phase III Randomized Trial of Gemtuzumab Combined with Conventional Chemotherapy for de novo Acute Myeloid Leukemia in Children, from 2004 until the 2010 and which led to the FDA approval of this agent in children. Dr. Gamis has served as a member of the COG Myeloid Scientific Disease Committee since 1996 and served as Chair of the committee from 2007-2013 overseeing all aspects of Myeloid Leukemia research (design, implementation, analysis, and strategic planning) during which time there was designed and developed numerous clinical trials in childhood AML. He has also served on the COG Epidemiology Steering Committee from 1992-1995 and the COG Stem Cell Transplant Steering Committee from 2002 to 2010. He was a founding member of the Pediatric Blood and Marrow Transplant Consortium (PBMTC) (now known as Pediatric Transplantation & Cellular Therapy Consortium (PTCTC)) beginning in 1992 ultimately serving as its Chair from 1999-2004 during which time he led the successful attainment of the UO1 NHLBI grant as an original clinical core center PI of the Bone Marrow Transplant Clinical Trials Network (BMT CTN). During this time he successfully joined the PBMTC with the COG through the NIH grant BAA-RM-04-23 grant, Re-engineering the Clinical Research Enterprise: Feasibility of Integrating and Expanding Clinical Research Networks, from 2004-2008. Since 2016, Dr Gamis has served on the NCI PDQ Pediatric Editorial Board overseeing the AML & Myeloid Disorders summary. Locally, he was the Director of the Children's Mercy Cancer Center from 1999-2023, and oversaw all clinical and research activities related to cancer care and successfully oversaw the program's expansion, program development and ultimately consortium institutional partnership with the NCI-designated University of Kansas Cancer Center. Since 2021, Dr Gamis has served as the Interim Division Director of the Division of Hematology/Oncology/Bone Marrow Transplantation.

One or more keywords matched the following items that are connected to Gamis, Alan

Item TypeName
Concept Down Syndrome
Academic Article Transient myeloproliferative disorder, a disorder with too few data and many unanswered questions: does it contain an important piece of the puzzle to understanding hematopoiesis and acute myelogenous leukemia?
Academic Article Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis.
Academic Article Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891.
Academic Article Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
Academic Article Acute myeloid leukemia and Down syndrome evolution of modern therapy--state of the art review.
Academic Article Exposure to medical test irradiation and acute leukemia among children with Down syndrome: a report from the Children's Oncology Group.
Academic Article Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome.
Academic Article Vitamin supplement use among children with Down's syndrome and risk of leukaemia: a Children's Oncology Group (COG) study.
Academic Article Congenital abnormalities and acute leukemia among children with Down syndrome: a Children's Oncology Group study.
Academic Article Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971.
Academic Article Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group.
Academic Article Transient myeloproliferative disorder in children with Down syndrome: clarity to this enigmatic disorder.
Academic Article Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes.
Academic Article Immune-related conditions and acute leukemia in children with Down syndrome: a Children's Oncology Group report.
Academic Article Health-related Quality of Life (HR-QOL) and Chronic Health Conditions in Survivors of Childhood Acute Myeloid Leukemia (AML) with Down Syndrome (DS): A Report From the Children's Oncology Group.
Academic Article Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.
Academic Article Pathologic Features of Down Syndrome Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML0431.
Academic Article High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial.
Academic Article Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children's Oncology Group.

Search Criteria
  • Down Syndrome